Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

Biotechnology

Healthcare
$0.33 -6.21%

-$0.10 today

Market cap
$62.85M
Beta
2.76
P/E (TTM)
-1.2
EPS (TTM)
-$1.24
52W Low $0.72High $3.65

Volume 1.79M

Average 2.02M

Returns on capital

Neumora Therapeutics, Inc. Common Stock management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-228.1%

avg -22.3%

ROIC

-151.8%

avg -60.7%

ROA

-124.0%

avg -54.9%

Analysis

ROA is currently the strongest return metric at -124.0% versus its period average of -54.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Joshua Pinto

President, Chief Executive Officer & DirectorUSD 2.1M42500.00K0.27%

Daljit Singh Aurora

Chief Operationg and development officerUSD 1.75M580<0.01%

Paul L. Berns

Executive ChairmanUSD 1.24M59500.00K0.27%

Jason G. Duncan

Chief Legal & Administrative OfficerUSD 315K52——

Nicholas Brandon

Chief Scientific Officer—51——

Andrew C. Lam

Senior VP of Technical Operations & Development————

David Phillips

Senior Vice President & Head of Quality————

Michael Lee Milligan

Chief Financial Officer & Principal Accounting Officer—53175.00K0.09%

Amy Sullivan

Chief Human Resources Officer————

Pablo Gersberg

Chief Information Officer————

Helen Rubinstein

Head of Investor Relations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 21, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

15

$784,229.14

Net Transaction Value

−$784,229.14

Net selling

Most Active

Aurora Daljit Singh

12 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 21, 26

Aurora Daljit Singh

Direct

Sell$32.8K
Aug 21, 26

Aurora Daljit Singh

Indirect

Sell$33.6K
Aug 20, 26

Aurora Daljit Singh

Indirect

Sell$101K
Aug 20, 26

Aurora Daljit Singh

Direct

Sell$102.6K
Aug 19, 26

Aurora Daljit Singh

Indirect

Sell$50.9K
Aug 19, 26

Aurora Daljit Singh

Direct

Sell$51K
Aug 18, 26

Aurora Daljit Singh

Direct

Sell$54.1K
Aug 18, 26

Aurora Daljit Singh

Indirect

Sell$55.5K
Aug 17, 26

Aurora Daljit Singh

Direct

Sell$50.5K
Aug 17, 26

Aurora Daljit Singh

Indirect

Sell$82.8K

1–10 of 15

Summary

Insiders reported 0 buys worth $0.00 and 15 sells worth $784,229.14 over the last 12 months. That adds up to net selling of $784,229.14. Aurora Daljit Singh was the most active insider with 12 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A7 analysts
Net IncomeN/AN/AN/A
N/A7 analysts
EBITN/AN/AN/A
N/A7 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Neumora Therapeutics, Inc. Common Stock compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NMRA's management, answered from reported figures.

Who manages NMRA?

Neumora Therapeutics, Inc. Common Stock (NMRA) lists 11 active executives. The top listed executive is Daljit Singh Aurora, Chief Operationg and development officer.

Are NMRA insiders buying or selling?

Recent insider activity shows net selling of $3.30M.